PDCD1 and hematopoietic and lymphoid cell neoplasm: Currently, multiple clinical trials are ongoing utilizing anti-PD1/PD-L1 antibodies, alone or in combination with other checkpoint blockade antibodies, antiangiogenic bevacizumab, or chemotherapy to treat solid and hematological tumors.